Lyell Immunopharma (LYEL) Income towards Parent Company (2020 - 2025)

Historic Income towards Parent Company for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$34.0 million.

  • Lyell Immunopharma's Income towards Parent Company rose 2369.33% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 7161.37%. This contributed to the annual value of -$334.7 million for FY2024, which is 4971.13% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Income towards Parent Company stood at -$34.0 million, which was up 2369.33% from -$43.9 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Income towards Parent Company ranged from a high of -$11.3 million in Q4 2022 and a low of -$196.2 million during Q4 2024
  • For the 5-year period, Lyell Immunopharma's Income towards Parent Company averaged around -$57.0 million, with its median value being -$52.4 million (2023).
  • Per our database at Business Quant, Lyell Immunopharma's Income towards Parent Company soared by 7600.13% in 2022 and then tumbled by 36266.0% in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Income towards Parent Company stood at -$47.2 million in 2021, then surged by 76.0% to -$11.3 million in 2022, then crashed by 362.66% to -$52.4 million in 2023, then crashed by 274.31% to -$196.2 million in 2024, then skyrocketed by 82.68% to -$34.0 million in 2025.
  • Its Income towards Parent Company stands at -$34.0 million for Q3 2025, versus -$43.9 million for Q2 2025 and -$53.5 million for Q1 2025.